SEC Comment Letter for Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260) (FBIO) — Sep 23, 2011

Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260)
Date: Sept. 23, 2011 · CIK: 0001429260 · Accession: 0000000000-11-056706

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-54463

Date

September 23, 2011

Author

Jeffrey Riedler

Form

UPLOAD

Company

Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260)

Letter

September 23, 2011 Via E-mail Bobby W. Sandage, Jr., Ph.D. President and Chief Executive Officer Coronado Biosciences, Inc. 15 New England Executive Park Burlington, MA 01803 Re: Coronado Biosciences, Inc. Registration Statement on Form 10-12G Filed July 15, 2011 File No. 000-54463

Dear Dr. Sandage: We have completed our review of your f ilings. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi lings to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely,

/s/ Bryan J. Pitko for

Jeffrey Riedler Assistant Director cc: Fran Stoller, Esq. Loeb & Loeb LLP 345 Park Avenue New York, NY 10154

Show Raw Text

September 23, 2011
 Via E-mail

Bobby W. Sandage, Jr., Ph.D. President and Chief Executive Officer Coronado Biosciences, Inc.  15 New England Executive Park Burlington, MA 01803
Re: Coronado Biosciences, Inc.
Registration Statement on Form 10-12G Filed July 15, 2011
 File No. 000-54463

Dear Dr. Sandage:
We have completed our review of your f ilings.  We remind you that our comments or
changes to disclosure in res ponse to our comments do not for eclose the Commission from taking
any action with respect to the company or the filings and the company may not assert staff
comments as a defense in any proceeding ini tiated by the Commission or any person under the
federal securities laws of the United States.  We urge all pers ons who are responsible for the
accuracy and adequacy of the disclosure in the fi lings to be certain that the filing includes the
information the Securities Exchange Act of 1934 and all applicable rules require.
 Sincerely,

            /s/ Bryan J. Pitko for

Jeffrey Riedler Assistant Director
   cc: Fran Stoller, Esq.
Loeb & Loeb LLP 345 Park Avenue  New York, NY 10154

SecProbe.io